NovaBay Pharmaceuticals, Inc. (NovaBay) is a biopharmaceutical company. The Company operates through four segments: dermatology, ophthalmology, urology and wound care. The dermatology segment includes NovaBay's business around the dermatology area, including the collaboration with Galderma and their impetigo clinical trial. The dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. The ophthalmology segment includes Avenova and its clinical trial on ophthalmology which it was conducting on its own. The ophthalmology segment also includes the i-Case product which is in development phases. The urology segment includes its urinary catheter encrustation and blockage (UCBE) trials. NovaBay completed Phase II clinical study of auriclosene to reduce UCBE. The wound care segment includes the business of NeutroPhase product. Its products under development stage include Aganocide Compounds.